ICU Medical Inc (STU:IC7)

Q2 2025 ICU Medical Inc Earnings Call Transcript

Aug 7, 2025 / 08:30 PM GMT

Release Date Price: €108

Transcript 10-Q8-K

Key Points

Positve

ICU Medical Inc (ICUI) reported Q2 revenue of $544 million, in line with expectations, showing a 2% organic growth.
The company's consumables business achieved a record quarter with 4% organic growth, driven by new global cost initiatives and price improvements.
ICU Medical Inc (ICUI) received additional 510(k) clearance for its clave neutral displacement connectors, which are associated with lower patient infection rates.
The IV systems business saw 2% organic growth, with double-digit growth in LVP installations.
Adjusted diluted earnings per share increased to $2.10 from $1.56 last year, reflecting strong financial performance.

Negative

The impact of tariffs is significant, with an expected expense of $25 to $30 million for FY25, affecting profitability.
The IV solutions revenues were deconsolidated, leading to a 34% reported decline in the vital care segment.
Currency fluctuations have not been as favorable as earlier in the quarter, impacting key selling geographies.
The company is facing challenges with tariffs, particularly with a recent increase in Costa Rica from 10% to 15%.
Despite efforts to mitigate, tariffs are expected to have a $10 million net impact on the P&L for the year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ICUI.OQ - ICU Medical Inc
Q2 2025 ICU Medical Inc Earnings Call
Aug 07, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by.

We're about to begin.

Good afternoon, everyone, and welcome to today's ICU medical 2nd quarter 2025 earnings conference call.

All participants will be in listen-only mode after today's presentation, there will be an opportunity to ask questions

To ask a question at that time, please press one.

Also, please note that today's event is being recorded.

I would now like to turn a conference over to Mr. John Mills, managing partner at ICR.

Please go ahead, sir.

Thank you and thank you for joining us to discuss ICU Medical's financial results, the 2nd quarter of 2025.

On the call today representing executive Office Chairman and Brian Bonnell,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.